
Butterfly Network Net Income | BFLY
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Butterfly Network
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -77.1 M | -72.5 M | -134 M | -169 M | -32.4 M | -163 M | -99.7 M | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -32.4 M | -169 M | -107 M |
Quarterly Net Income Butterfly Network
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.8 M | -12.9 M | -12.7 M | -15.3 M | -34 M | -13.8 M | -14 M | -18.1 M | -16.9 M | -15.7 M | -21.8 M | -44.1 M | -27.4 M | -28.7 M | -33.5 M | -33.7 M | -54.7 M | -35.8 M | -44.5 M | -15.2 M | -13.6 M | -2.94 M | -690 K | -22.9 M | -92.2 M | -23.2 M | -24.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -690 K | -92.2 M | -25.4 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Establishment Labs Holdings
ESTA
|
-51.1 M | $ 70.8 | 1.86 % | $ 2.1 B | ||
|
Medtronic PLC
MDT
|
4.8 B | $ 100.7 | -1.58 % | $ 129 B | ||
|
Myomo
MYO
|
-15.6 M | $ 0.88 | -3.85 % | $ 36.8 M | ||
|
MiMedx Group
MDXG
|
48.6 M | $ 3.2 | 0.63 % | $ 473 M | ||
|
Delcath Systems
DCTH
|
2.7 M | $ 19.7 | 1.7 % | $ 706 M | ||
|
Electromed
ELMD
|
11.3 M | $ 23.59 | 1.99 % | $ 195 M | ||
|
Inogen
INGN
|
22.7 M | $ 5.58 | -1.85 % | $ 148 M | ||
|
Globus Medical
GMED
|
538 M | $ 70.5 | 0.73 % | $ 9.53 B | ||
|
Quanterix Corporation
QTRX
|
-107 M | $ 2.07 | -27.62 % | $ 88.3 M | ||
|
IRadimed Corporation
IRMD
|
22.5 M | $ 82.34 | -1.33 % | $ 1.05 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
-75 M | $ 0.26 | -8.45 % | $ 16.8 M | ||
|
ClearPoint Neuro
CLPT
|
-25.5 M | $ 7.77 | -1.21 % | $ 220 M | ||
|
Accuray Incorporated
ARAY
|
-49.2 M | $ 2.49 | 2.05 % | $ 305 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | ||
|
AxoGen
AXGN
|
-15.7 M | $ 56.98 | 2.9 % | $ 2.62 B | ||
|
IRIDEX Corporation
IRIX
|
-4.44 M | $ 0.5 | -28.53 % | $ 8.47 M | ||
|
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 5.1 | 12.83 % | $ 317 M | ||
|
Sensus Healthcare
SRTS
|
-7.72 M | $ 2.3 | 1.55 % | $ 37.6 M | ||
|
Stryker Corporation
SYK
|
849 M | $ 318.0 | 0.14 % | $ 122 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
-517 M | $ 13.87 | 2.32 % | $ 1.06 B | ||
|
Tactile Systems Technology
TCMD
|
19.1 M | $ 26.45 | 1.54 % | $ 605 M | ||
|
Bruker Corporation
BRKR
|
-8.3 M | $ 63.28 | 3.13 % | $ 9.61 B | ||
|
LivaNova PLC
LIVN
|
-242 M | $ 94.44 | 2.74 % | $ 5.15 B | ||
|
Tandem Diabetes Care
TNDM
|
-205 M | $ 16.97 | -0.53 % | $ 1.15 B | ||
|
Profound Medical Corp.
PROF
|
-42.6 M | $ 6.87 | -2.97 % | $ 208 M | ||
|
LENSAR
LNSR
|
-34.3 M | $ 4.91 | -0.07 % | $ 58.7 M | ||
|
Orthofix Medical
OFIX
|
-92.2 M | $ 6.59 | -1.27 % | $ 261 M | ||
|
Pulmonx Corporation
LUNG
|
-54 M | $ 2.69 | -1.83 % | $ 109 M | ||
|
InspireMD
NSPR
|
-48.8 M | $ 0.68 | 4.58 % | $ 43.7 M | ||
|
InMode Ltd.
INMD
|
93.8 M | $ 12.87 | -0.43 % | $ 832 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 31.67 | 0.81 % | $ 743 M | ||
|
Outset Medical
OM
|
-81.7 M | $ 3.04 | -3.8 % | $ 46.2 M | ||
|
PAVmed
PAVM
|
-3.77 M | $ 1.3 | -13.91 % | $ 872 K | ||
|
AVITA Medical
RCEL
|
-48.6 M | $ 16.71 | 5.96 % | $ 466 M | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 1.21 | -2.42 % | $ 3.36 M | ||
|
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | ||
|
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | ||
|
Beyond Air
XAIR
|
34.3 K | $ 1.84 | -8.46 % | $ 15.3 B | ||
|
Xtant Medical Holdings
XTNT
|
4.97 K | $ 0.21 | 3.74 % | $ 29.3 M | ||
|
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | ||
|
Vivos Therapeutics
VVOS
|
-21.2 M | $ 0.08 | -5.9 % | $ 822 K | ||
|
Varex Imaging Corporation
VREX
|
-70.3 M | $ 18.14 | 0.19 % | $ 751 M | ||
|
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 7.38 | -2.06 % | $ 997 M | ||
|
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | ||
|
Inspire Medical Systems
INSP
|
145 M | $ 58.04 | -2.31 % | $ 1.7 B | ||
|
Integer Holdings Corporation
ITGR
|
103 M | $ 126.97 | -0.01 % | $ 4.41 B | ||
|
Avanos Medical
AVNS
|
-72.9 M | $ 24.99 | - | $ 1.16 B | ||
|
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M |